

# UC Davis

## UC Davis Previously Published Works

### Title

From MDS/AML to iPSC and back again.

### Permalink

<https://escholarship.org/uc/item/4hn2v49s>

### Journal

Science Translational Medicine, 9(380)

### ISSN

1946-6234

### Author

Jonas, Brian A

### Publication Date

2017-03-08

### DOI

10.1126/scitranslmed.aam9861

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed



Advertisement



Institution: UNIV OF CALIFORNIA - DAVIS   Log in   My account   Contact Us  
[Become a member](#)   Renew my subscription   Sign up for newsletters



**EDITORS' CHOICE** | CANCER

## From MDS/AML to iPSC and back again

Brian A. Jonas

*Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA. Email: [bajonas@ucdavis.edu](mailto:bajonas@ucdavis.edu)*

[+ See all authors and affiliations](#)

*Science Translational Medicine* 08 Mar 2017:  
Vol. 9, Issue 380,  
DOI: 10.1126/scitranslmed.aam9861

Article

Info & Metrics

eLetters

### Abstract

iPSC lines derived from MDS and AML patient samples can map clonal evolution, disease progression and regression, and identify disease stage-specific medication effects.

Acute myeloid leukemia (AML) is an aggressive clonal blood and bone marrow cancer that can arise de novo or from preexisting hematologic diseases, such as myelodysplastic syndromes (MDS). It is now well established that AML evolves from hematopoietic stem and progenitor cells (HSPCs) through the step-wise accumulation of multiple genetic changes. However, functional studies of the evolution from MDS to AML are limited by the relative inability of primary MDS cells to grow and transplant. Patient-derived induced pluripotent stem cells (iPSCs) are being evaluated as potential platforms for studying cancer progression,

genetics, and treatment, including a recent report by Kotini *et al.* investigating iPSCs derived from patients with myeloid diseases.

Using primary MDS and AML patient samples, Kotini *et al.* developed a reprogrammed panel of patient-derived iPSC lines spanning the entire myeloid disease spectrum, including normal, preleukemic, MDS, and AML stages. Notably, the reprogramming potential of each patient sample was mutation-specific. The investigators selected iPSC lines representative of different disease stages and used a hematopoietic differentiation protocol to characterize the phenotype of each disease stage-specific line. Hematopoietic progenitor cells (HPCs) derived from these iPSC lines demonstrated graded disease stage-specific changes in dysplasia, progenitor loss, differentiation block, cell growth rate, gene expression, and engraftment in NOD/SCID/IL-2 $\gamma^{\text{null}}$  mice that mapped the phenotypic transformation from normal HSPCs to fulminant and serially transplantable leukemia. Next, the investigators used genome-editing methods to model clonal evolution and showed that iPSC lines from distinct disease stages could be transitioned forward or backward through the introduction or correction of specific mutations. Last, iPSC-derived HPCs showed disease stage-specific responses to drug treatment.

This study used cell reprogramming and genetics to develop a panel of patient-derived, disease stage-specific iPSC lines that provides a phenotypic roadmap of myeloid disease progression and can be custom tailored through genome editing approaches. The small number of primary patient samples and inability of some cells with specific mutations to reprogram are limitations; overall, however, stage-specific iPSC lines represent a powerful new tool for functional studies of myeloid diseases, demonstrating proof of principle that treatment effects can be studied in these models with potentially broader cancer applicability.

## Highlighted Article

A. G. Kotini, C. J. Chang, A. Chow, H. Yuan, T. C. Ho, T. Wang, S. Vora, A. Solovyov, C. Husser, M. Olszewska, J. Teruya-Feldstein, D. Perumal, V. M. Klimek, A. Spyridonidis, R. K. Rampal, L. Silverman, E. P. Reddy, E. Papaemmanuil, S. Parekh, B. D. Greenbaum, C. S. Leslie, M. G. Kharas, E. P. Papapetrou, Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. *Cell Stem Cell* **20**, 315–328.e7 (2017). [UC-eLinks](#) [UC-eLinks](#) [Google Scholar](#)

Copyright © 2017, American Association for the Advancement of Science

## View Abstract



Science Translational Medicine

Vol 9, Issue 380

08 March 2017

[Table of Contents](#)

## ARTICLE TOOLS

- Email
- Save to my folders
- Alerts
- Request Permissions
- Citation tools
- Share

Advertisement

An advertisement for a Tableau whitepaper. The background is black with numerous small, glowing orange and red dots of varying sizes, resembling a starry night sky or data points. The text is centered and reads: "TOP TEN Big Data TRENDS FOR 2017". Below this, there is a white rectangular button with the text "GET THE WHITEPAPER". At the bottom, the Tableau logo is displayed, consisting of a cluster of white plus signs followed by the word "tableau" in a lowercase, sans-serif font. A small blue 'X' icon is in the top right corner of the ad area.

TOP TEN  
Big Data  
TRENDS FOR 2017

GET THE WHITEPAPER

tableau

## SIMILAR ARTICLES IN:

- [Google Scholar](#)

Advertisement



**NAVIGATE THIS ARTICLE**

- [Article](#)
  - [Abstract](#)
  - [Highlighted Article](#)
- [Info & Metrics](#)
- [eLetters](#)

## Science

3 March 2017

Vol 355, Issue 6328

**FEATURE**

**Into the Twilight Zone**

**POLITICAL SCIENCE**

**The need for a translational science of democracy**

**EXHIBITION**

**Deep exposures**

**SCI COMMUN**

**News at a glance**

**PLANT PATHOGENS**

## Durable resistance to rice blast

### WORKING LIFE

## Sailing through uncertainty

Table of Contents

Subscribe Today

Receive a year subscription to *Science* plus access to exclusive AAAS member resources, opportunities, and benefits.

Subscribe Today

## Get Our Newsletters

Enter your email address below to receive email announcements from Science. We will also send you a newsletter digest with the latest published articles. [See full list](#)

- Science Translational Medicine TOC
- Science* Table of Contents
- Science* Daily News
- Science* News This Week
- Science* Editor's Choice
- First Release Notification

Sign up today

## About us

[About journals](#)

[Leadership](#)

[Team members](#)

[Work at AAAS](#)

## Advertise

[Advertising kits](#)

[Custom publishing](#)

## For subscribers

[Site license info](#)

[For members](#)

## International

[Chinese](#)

Japanese

## Help


[Access & subscriptions](#)

[Reprints & permissions](#)

[Contact us](#)

[Accessibility](#)

## Stay Connected



© 2017 American Association for the Advancement of Science. All rights Reserved. AAAS is a partner of HINARI, AGORA OARE, PatientInform, CHORUS, CLOCKSS, CrossRef and COUNTER. *Science Translational Medicine* ISSN 1946-6242.

[Terms of Service](#)

[Privacy Policy](#)

[Contact Us](#)